Darren Pan, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A446
San Francisco CA 94117
PronounsHe/Him/His
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    David Geffen School of Medicine at UCLAMD06/2017Medicine
    Icahn School of Medicine at Mount SinaiResidency06/2020Internal Medicine
    Icahn School of Medicine at Mount SinaiFellowship06/2024Hematology and Medical Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Pan is a hematologist/oncologist specializing in the care of patients with multiple myeloma and other blood cancers. He earned his medical degree from UCLA's David Geffen School of Medicine and completed his residency in internal medicine, followed by a fellowship in hematology/oncology at the Icahn School of Medicine at Mount Sinai. Dr. Pan conducts research identifying cutting-edge treatment options for patients with multiple myeloma with a focus towards immunotherapies. He provides comprehensive care to patients both in the clinic and hospital, including those undergoing bone marrow transplants and advanced cellular therapies like CAR T cell therapy.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma. Curr Hematol Malig Rep. 2024 Aug 15. Pan D, Richter J. PMID: 39145912.
      View in: PubMed   Mentions:    Fields:    
    2. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024 Aug 13; 8(15):3859-3869. Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, Fein JA, Monge J, Rosenbaum C, Pearse R, Jayabalan D, Gordillo C, Chan HT, Yamshon S, Thibaud S, Mapara M, Inghirami G, Lentzsch S, Reshef R, Rossi A, Parekh S, Jagannath S, Richard S, Niesvizky R, Bustoros M. PMID: 38776397; PMCID: PMC11321283.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant. 2024 Jul 31. Avigan ZM, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, Milkovich G, Chari A, Richter J. PMID: 39085373.
      View in: PubMed   Mentions:    Fields:    
    4. Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States. EJHaem. 2023 Nov; 4(4):984-994. Richter J, Pan D, Salinardi T, Rice MS. PMID: 38024614; PMCID: PMC10660406.
      View in: PubMed   Mentions: 1  
    5. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody. Cancer Manag Res. 2023; 15:741-751. Pan D, Richter J. PMID: 37497430; PMCID: PMC10368105.
      View in: PubMed   Mentions: 3  
    6. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. Blood Adv. 2023 03 28; 7(6):1056-1064. Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. PMID: 36018226; PMCID: PMC10033902.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    7. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Semin Oncol. 2023; 50(1-2):40-48. Pan D, Mouhieddine TH, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. PMID: 37005144.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Front Oncol. 2021; 11:819127. Pan D, Richter J. PMID: 35127532; PMCID: PMC8811139.
      View in: PubMed   Mentions: 7  
    9. Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer Med. 2022 01; 11(2):358-370. Pan D, Kaufman JL, Htut M, Agrawal M, Mazumder A, Cornell RF, Zonder JA, Fay JW, Modiano MR, Moshier EL, Rush SA, Tunquist BJ, Chari A. PMID: 34921527; PMCID: PMC8729045.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    10. Pre-hospital antiplatelet medication use on COVID-19 disease severity. Heart Lung. 2021; 50(5):618-621. Pan D, Ip A, Zhan S, Wasserman I, Snyder DJ, Agathis AZ, Shamapant N, Yang JY, Pai A, Mazumdar M, Poor H. PMID: 34090177; PMCID: PMC8156906.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    11. Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience. Clin Lymphoma Myeloma Leuk. 2021 Jul; 21(7):439-443. Pan D, Coltoff A, Ozbek U, Lin JY, Afshar S, Galitzeck Z, Steinberg A. PMID: 33757769.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. Blood Adv. 2020 Mar 10; 4(5):970-982. Pan D, Rampal R, Mascarenhas J. PMID: 32150613; PMCID: PMC7065485.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    13. Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant. 2018 08; 24(8):1715-1720. Molina A, Winston DJ, Pan D, Schiller GJ. PMID: 29555315.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    Darren's Networks
    Concepts (47)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (3)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.